Glycogen Storage Disease Diagnosis and Management

Glycogen storage diseases (GSDs) constitute a group of inherited metabolic disorders characterised by defects in enzymes responsible for the synthesis or breakdown of glycogen, leading to variable accumulation of abnormal glycogen in liver, muscle or other tissues. Clinical presentation ranges from hypoglycaemia and hepatomegaly in infancy to progressive myopathy and cardiomyopathy in adulthood. Diagnosis typically combines clinical assessment with biochemical assays of enzyme activity in blood, liver or muscle biopsies, molecular genetic testing of causative genes and non-invasive imaging modalities to assess organ involvement. Management aims to maintain euglycaemia, prevent secondary organ damage and optimise quality of life through tailored nutritional support (including frequent feeds, uncooked cornstarch and specialised macronutrient compositions), adjunctive pharmacological strategies and, in selected cases, organ transplantation. Emerging approaches encompass gene therapy, small-molecule modulation of cellular clearance pathways and precision dietary regimens informed by long-term natural history studies. A multidisciplinary framework involving metabolic physicians, dietitians, geneticists and allied health professionals underpins optimal care and drives ongoing research into curative interventions.

Research from Nature Portfolio

Recent studies have elucidated the atomic structure of the human glycogen debranching enzyme, revealing distinct catalytic domains responsible for sequential α-1,4 transfer and α-1,6 glycosidic cleavage. High-resolution crystallography identified surface residues that mediate substrate recruitment and regulate enzymatic activity beyond the active site. Structure-guided mutagenesis clarified the molecular basis by which disease-causing mutations disrupt tertiary contacts, impair binding to glycogen and alter catalytic efficiency. These foundational insights into enzyme mechanism now inform the rational design of stabilised enzyme variants and small-molecule activators aimed at restoring function in patients with type III GSD.

Glycogen Storage Disease Diagnosis and Management publication trend

The graph below shows the total number of articles in glycogen storage disease diagnosis and management across all publications each year (not limited to Nature Index journals).

Technical terms

Glycogen debranching enzyme: Multifunctional enzyme that catalyses transfer of α-1,4 oligosaccharide chains and cleavage of α-1,6 linkages in glycogen.

Polyglucosan: Abnormally branched or poorly branched glycogen polymer that accumulates in certain GSDs due to enzyme defects.

Autophagy: Intracellular degradation pathway in which cytoplasmic cargo, including glycogen aggregates, is delivered to lysosomes for clearance.

Adeno-associated virus (AAV) vector: Non-pathogenic viral delivery system widely used in gene therapy to introduce functional copies of defective genes into target cells.

Uncooked cornstarch: Slowly digested complex carbohydrate used as a continuous glucose source to prevent hypoglycaemia in GSD patients.

References

1. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. Journal of Inherited Metabolic Disease (2016).
2. Crystal structure of glycogen debranching enzyme and insights into its catalysis and disease-causing mutations. Nature Communications (2016).
3. The Autophagic Activator GHF-201 Can Alleviate Pathology in a Mouse Model and in Patient Fibroblasts of Type III Glycogenosis. Biomolecules (2024).
4. Long‐term personalized high‐protein, high‐fat diet in pediatric patients with glycogen storage disease type IIIa: Evaluation of myopathy, metabolic control, physical activity, growth, and dietary compliance. Journal of Inherited Metabolic Disease (2024).
5. Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model. JCI Insight (2024).